Northwestern Mutual Investment Management Company LLC lowered its stake in Zoetis Inc. (NYSE:ZTS) by 5.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,112,569 shares of the company’s stock after selling 65,279 shares during the period. Zoetis makes up about 1.1% of Northwestern Mutual Investment Management Company LLC’s portfolio, making the stock its 14th largest position. Northwestern Mutual Investment Management Company LLC owned approximately 0.22% of Zoetis worth $52,803,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Ngam Advisors L.P. increased its stake in shares of Zoetis by 88.0% in the second quarter. Ngam Advisors L.P. now owns 200,416 shares of the company’s stock valued at $9,512,000 after buying an additional 93,838 shares during the last quarter. Cullen Frost Bankers Inc. increased its stake in shares of Zoetis by 0.7% in the second quarter. Cullen Frost Bankers Inc. now owns 347,368 shares of the company’s stock valued at $16,486,000 after buying an additional 2,470 shares during the last quarter. Columbus Circle Investors increased its stake in shares of Zoetis by 43.9% in the second quarter. Columbus Circle Investors now owns 477,128 shares of the company’s stock valued at $22,644,000 after buying an additional 145,641 shares during the last quarter. Legal & General Group Plc increased its stake in shares of Zoetis by 0.9% in the first quarter. Legal & General Group Plc now owns 2,104,616 shares of the company’s stock valued at $93,293,000 after buying an additional 18,063 shares during the last quarter. Finally, York Capital Management Global Advisors LLC acquired a new stake in shares of Zoetis during the first quarter valued at $49,823,000. 93.89% of the stock is currently owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Zoetis Inc. (NYSE:ZTS) opened at 50.61 on Monday. Zoetis Inc. has a one year low of $38.26 and a one year high of $53.14. The firm has a market cap of $24.99 billion, a PE ratio of 36.49 and a beta of 1.05. The stock has a 50 day moving average of $50.68 and a 200 day moving average of $49.45.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Wednesday, November 2nd. The company reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.06. The firm had revenue of $1.20 billion for the quarter, compared to analysts’ expectations of $1.22 billion. Zoetis had a net margin of 14.10% and a return on equity of 72.96%. Zoetis’s revenue was up 2.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.50 earnings per share. On average, equities analysts forecast that Zoetis Inc. will post $1.94 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 1st. Shareholders of record on Thursday, November 3rd will be given a dividend of $0.095 per share. The ex-dividend date is Tuesday, November 1st. This represents a $0.38 dividend on an annualized basis and a yield of 0.75%. Zoetis’s dividend payout ratio (DPR) is 27.54%.

A number of brokerages have commented on ZTS. Zacks Investment Research raised shares of Zoetis from a “hold” rating to a “buy” rating and set a $56.00 price objective on the stock in a research report on Monday, November 7th. JPMorgan Chase & Co. reissued a “hold” rating and issued a $53.00 price objective on shares of Zoetis in a research report on Thursday, November 3rd. Jefferies Group reissued a “buy” rating and issued a $63.00 price objective on shares of Zoetis in a research report on Sunday, October 16th. Stifel Nicolaus reissued a “buy” rating and issued a $58.00 price objective on shares of Zoetis in a research report on Wednesday, October 12th. Finally, Bank of America Corp. began coverage on shares of Zoetis in a research report on Thursday, September 29th. They issued a “buy” rating and a $60.00 price objective on the stock. Two analysts have rated the stock with a sell rating, three have given a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $55.92.

In other Zoetis news, insider Heidi C. Chen sold 32,097 shares of Zoetis stock in a transaction that occurred on Thursday, September 1st. The shares were sold at an average price of $50.98, for a total transaction of $1,636,305.06. Following the transaction, the insider now directly owns 46,060 shares of the company’s stock, valued at $2,348,138.80. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Andrew Fenton sold 13,870 shares of Zoetis stock in a transaction that occurred on Friday, September 2nd. The shares were sold at an average price of $51.25, for a total transaction of $710,837.50. Following the transaction, the insider now directly owns 17,719 shares in the company, valued at $908,098.75. The disclosure for this sale can be found here. Company insiders own 0.05% of the company’s stock.

About Zoetis

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

5 Day Chart for NYSE:ZTS

Receive News & Stock Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related stocks with our FREE daily email newsletter.